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ABSTRACT
Objective: Patients with cancer have antibodies against
tumour antigens. Characterising the antibody repertoire
may provide insights into aberrant cellular mechanisms in
cancer development, ultimately leading to novel diag-
nostic or therapeutic targets. The aim of this study was to
characterise the antibody profiles in patients whose
symptoms warranted colonoscopy, to see if there was a
difference in patients with and without colorectal cancer.
Methods: Patients were recruited from a colonoscopy
clinic. Individual serum samples from 43 patients with
colorectal cancer and 40 patients with no cancer on
colonoscopy were profiled on a 37 830 clone recombinant
human protein array. Antigen expression was evaluated
by quantitative reverse transcription-PCR and by immu-
nohistochemistry on tissue microarrays.
Results: Using a sex- and age-matched training set, 18
antigens associated with cancer and 4 associated with
the absence of cancer (p,0.05) were identified and
confirmed. To investigate the mechanisms triggering
antibody responses to these antigens, antigen expression
was examined in normal colorectal mucosa and colorectal
carcinoma of the same patients. The identified antigens
showed cellular accumulation (p53), aberrant cellular
expression (high mobility group B1 (HMGB1)) and
overexpression (tripartite motif-containing 28 (TRIM28),
p53, HMGB1, transcription factor 3 (TCF3), longevity
assurance gene homologue 5 (LASS5) and zinc finger
protein 346 (ZNF346)) in colorectal cancer tissue
compared with normal colorectal mucosa.
Conclusions: It is demonstrated for the first time that
screening high-density protein arrays identifies unique
antibody profiles that discriminate between symptomatic
patients with and without colorectal cancer. The
differential expression of identified antigens suggests their
involvement in aberrant cellular mechanisms in cancer.
Colorectal cancer is the leading cause of cancer-
related mortality in the Western world. Deaths
from colorectal cancer can be prevented through
effective screening.1–3 Recent studies have defined
specific antibody responses to tumour-related
antigens in patients with cancer.4–8 Since these
antibodies are often triggered by changes in the
structure or expression of self proteins in tumour
cells,9 10 they may serve as potential immunological
markers of cancer.11 12
Various technologies have been used to identify
cancer-specific antibodies. Phage display offers a
powerful platform to identify antibody signatures.
However, phage display technology is labour
intensive, and peptides expressed by bacteriophage
often do not correspond to native antigens, thus
limiting identification of molecular targets in
cancer.13 Proteomics is a novel approach to identify
tumour antigens. This method largely relies on
tumour cells as a source for antigens. Detection of
low abundant proteins and membrane proteins is
problematic with this approach. Large protein
arrays provide a unique opportunity to profile
antibody signatures from libraries containing
thousands of different proteins. A significant
advantage of large protein arrays is that complex
antibody repertoires from cohorts of patients can
be easily identified.
In this study, we set out to characterise the
antibody profile of patients presenting to hospi-
tal whose symptoms warranted colonoscopy. We
screened .1800 patients until a cohort of 40 sex-
and age-matched patients, with and without
colorectal cancer, was identified. We charac-
terised the antibody profile in this training set
and then in an additional extended set of 23
patients with cancer and 20 patients without
cancer. In patients with colorectal cancer, we
identified a unique antibody signature consisting
of 18 markers. We demonstrate disease-associated
alterations in the expression of corresponding
antigens in tissue from patients with colorectal
cancer, which may serve as new diagnostic
markers or new therapeutic targets. For sympto-
matic patients without cancer, we also defined
an antibody signature consisting of four antigens,
which we termed ‘‘antimarkers’’.
Serum antibodies to p53, a known marker for
cancer, were identified as part of the cancer
signature. The expression of p53 in tissue from
patients with cancer was confirmed, showing
the utility of this screening approach. Serum
antibodies to the antigen high mobility group B1
(HMGB1) were found significantly more often
in patients with cancer. Immunohistochemistry
of colorectal cancer samples demonstrated aber-
rant HMGB1 expression in tissue. Other anti-
gens identified as a part of the colorectal cancer
antibody signature showed upregulation of their
corresponding genes in cancer tissue, foremost
the tripartite motif-containing 28 (TRIM28)
gene with overexpression in the majority of
analysed colorectal carcinomas. This study
demonstrates the utility of screening serum
samples with high-density protein arrays in
appropriate cohorts of patients. Our results
confirm the presence of antigens known to be
expressed in colorectal cancer and identify novel
Colon cancer
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antigens that may be important in the diagnosis and
treatment of cancer.
MATERIAL AND METHODS
Patients and samples
This study was approved by the Ethics (Medical) Research
Committee at Beaumont Hospital, Dublin. Informed consent
was obtained from all patients. A total of 1820 patients
undergoing colonoscopy were screened prospectively. The
clinical notes of all patients attending for colonoscopies were
reviewed daily by the clinical research nurses. Patients with a
history of cancer, systemic inflammatory or autoimmune
disease and patients taking immunosuppressive medication
were excluded from the study. The colonoscopy findings were
reviewed with the consultant physician and, if a diagnosis of
cancer or normal colonoscopy was made, then patients were
eligible to participate. Subjects were then asked to provide a
blood sample. In all patients with a clinical diagnosis of cancer,
histology findings were reviewed to confirm the diagnosis. In
total, 43 Caucasian patients with newly diagnosed colorectal
cancer and 40 Caucasian patients with no neoplasm of the colon
(non-cancer controls) fulfilled the inclusion criteria and were
recruited consecutively. From this cohort the 20 patients with
cancer and 20 sex- and age-matched non-cancer controls were
used as a training set to identify cancer- and non-cancer-
associated antibody profiles. The diagnosis of cancer was
independently verified on tissue samples by a pathologist.
Blood was obtained from all patients prior to chemotherapy,
radiation and surgical treatment. Serum was prepared and
stored at 280uC. Serum samples were coded and sent blinded
for antibody profiling.
Protein arrays
High-density protein arrays were used to screen serum samples
(hEx1, Imagenes, Berlin, Germany). The hEx1 human cDNA
library was directionally cloned in an Escherichia coli vector that
allows expression of His6-tagged fusion proteins in the presence
of isopropyl b-D-1-thiogalactopyranoside (IPTG). A total of
193 536 hEx1 clones were screened for expression of His6-
tagged fusion proteins. In total, 37 830 clones expressing
recombinant human proteins were identified and used for
generation of high-density protein arrays.14 15 The array has a
minimum of 10 000 unique proteins.
Serum screening
To identify immunoglobulin G (IgG) antibodies in serum of
patients, the hEx1 protein arrays were prepared as described.15 16
Briefly, hEx1 protein arrays were incubated with diluted serum
(1:100) for 16 h. Mouse antihuman IgG antibody (GG-7, Sigma-
Aldrich, St Louis, Missouri, USA), alkaline phosphatase (AP)-
conjugated goat antimouse IgG antibody (A1418, Sigma-Aldrich)
and the substrate Attophos (JBL Scientific, San Luis Obisco,
California, USA) were used as detection reagents (online
supplementary method 1). Images were captured with a Fuji
LAS 3000 imager.
Protein array analysis
High-resolution images of protein arrays incubated with serum
and detection antibodies were analysed using Visual Grid
software (GPC Biotech, Martinsried, Germany). Each clone on
the array is arrayed in duplicate; only clones showing distinct
signals in both positions on the array were defined as positive
(fig 1). Analysis of each protein array gave a list of positives
which corresponds to a unique antibody profile for every
subject. The unique antibody profile from each subject was
compared with that of all other subjects. The clones identified
in this analysis were then compared between patients with and
without cancer by Fisher exact test. False-positive signals caused
by binding of the detection antibodies (antihuman IgG and
antimouse AP antibodies) directly to proteins on the array were
identified by probing the protein array with the detection
antibodies in the absence of human serum. These clones were
excluded from the analysis.
Gene expression by real-time quantitative reverse transcription-
PCR (RT-PCR)
Gene expression of antigens identified in the serum profiling
was measured in tissue samples using real-time quantitative
RT-PCR (Taqman assay) with an ABI Prism 7500 Sequence
Detection System (Applied Biosystems, Foster City, California,
USA). Tumour and normal tissue were available for 16 of the 43
patients with colon cancer. All samples for gene expression
analysis were stored in RNAlater at 220uC. Total RNA was
extracted using Qiagen RNeasy spin columns (Qiagen, Hilden,
Germany) and cDNA was synthesised using Superscript II
reverse transcriptase (Invitrogen, Carlsbad, California, USA)
followed by PCR with Applied Biosystem’s 7500 Real-Time PCR
System. The mRNA levels of the gene of interest and that of the
internal standard (b-actin) were measured concurrently from
the same cDNA preparations. The comparative CT method was
used to quantitate gene expression.17 18 Briefly, the normalised
value of expression for the target gene with reference to b-actin
was obtained by 1/2DCT. 2DCT is derived from Xn = X0 (1+Ex)n,
where X0 is the initial number of target molecules, Ex the
efficiency of amplification, and n the number of cycles
(supplementary methods online). All mRNA expression values
are ratios relative to b-actin and are expressed as61023. For each
gene, n = 1 or 2, each consisting of three separate PCRs.
ZNF700 (zinc finger protein 700) primers and probes were
purchased as a ‘‘made to order’’ gene expression assay. b-Actin
primers and probes were purchased as a ready to use
predeveloped assay reagent (PDAR, Applied Biosystems) with
a 59 FAM (6-carboxy-fluorescein) reporter dye and 39 TAMRA
(6-carboxy-tetramethlrhodamine) quencher. All other primers
and probe sets were purchased as ready to use inventoried gene
expression assays (Applied Biosystems). Both ‘‘made to order’’
and inventoried probes are MGB (minor groove binding) with a
59 FAM reporter dye and 39 NFQ (non-fluorescent quencher).
Immunohistochemistry on tissue microarrays (TMAs)
TMAs were constructed from formalin-fixed, paraffin-
embedded tissue as previously described.19 20 Tissue from 43
patients with colorectal cancer and 19 patients with no
neoplasm of the colon, from surgical resections or biopsy
samples, was examined for antigen expression. All staining was
conducted on the BondMax automated immunohistochemical
staining platform (Vision BioSystems, Newcastle, UK). Sections
were incubated with primary antibody against p53 (DO-7,
Dako, Glostrup, Denmark) and HMGB1 (M02, Abnova,
Heidelberg, Germany). Detection and visualisation of stained
cells was achieved using the Bond Polymer Refine Kit (Vision
BioSystems) with DAB (diaminobenzidine) as the chromogen.
Statistical analysis
Fisher two-sided exact test was employed to compare frequen-
cies for each identified antigen in patients with colorectal cancer
Colon cancer
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and in non-cancer control subjects. A p value ,0.05 was
considered statistically significant. Statistically significant anti-
gens identified in the training set were reassessed in the
extended set. To correct for multiple testing of statistically
significant antigens, we applied the Bonferroni correction at a
level of a= 0.05 and the false discovery rate (FDR) method at a
level of q = 0.05, for both markers and antimarkers separately.
Sensitivity and specificity were calculated according to Altman
and Bland.21 For gene expression studies, mean ratios of tumour
to normal mRNA levels were shown with the standard error
(SE), and p values were determined using Wilcoxon signed-rank
test.
RESULTS
Patient samples
A total of 1820 patients attending the colonoscopy clinic were
screened. Initially, a training set of 20 patients with colorectal
cancer and 20 sex- and age-matched patients with no cancer
was identified. To identify a cancer-specific antibody signature
in patients with colorectal cancer, we analysed the frequencies
of antibody detection in this sex- and age-matched training set
(table 1). An additional 23 patients with colorectal cancer and
20 patients with no cancer were further characterised. All 20
patients with colorectal cancer and 20 patients without cancer
of the training set and the additional 23 patients with colorectal
cancer and 20 patients with no cancer of the extended set were
screened on high-density protein arrays, and individual profiles
were identified. The resulting antibody profiles identified in the
training set were further characterised in the extended cohort.
We identified an antibody signature for colorectal cancer
including antibodies against p53, HMGB1 and TRIM28. We
then characterised the protein and RNA expression of the
known cancer antigen p53 in tissue from this patient cohort to
validate our approach. In addition, we further characterised the
expression of HMGB1 by both protein and RNA expression.
The expression of TRIM28 and other identified antigens was
characterised by RNA levels alone to assess their potential as
molecular markers of cancer. The algorithm for analysis is
summarised in fig 2.
Antibody profiles
The antibody profiles for all 83 subjects were characterised
blinded to any clinical data. The antibody profile for each
subject was characterised. When two identical clones on the
array were recognised by serum antibodies, this was defined as
positive (fig 1). An average of 833 positives was identified for
each subject. Although individual profiles were unique, many of
the positives were shared by different individuals. Combining
the antibody profiles for the 83 subjects showed that 19 645
different clones were positive in one or more individuals. Thus
52% of the 37 830 clones present on the hEx1 protein array
were recognised by antibodies from the total cohort of
subjects. Of these clones, 11 703 were positive in two or more
sera. When the protein array data were analysed, the clinical
information was unblinded and the data were analysed as
patients with and without cancer (fig 3). The diagram
illustrates the heterogeneous distribution of antibodies among
Figure 1 High-density protein array. A
total of 37 830 clones expressing
recombinant human proteins are arrayed
in duplicate. The two signals shown in the
enlarged section of the array demonstrate
serum immunoglobulin G antibodies
binding to a clone arrayed twice in a
specific pattern. The 565 pattern shown
in the box below allows rapid and
accurate analysis and identification of
positive clones.
Table 1 Clinical characteristics of the training set
Patients with colorectal
cancer (n = 20)
Non-cancer controls
(n = 20)
Sex, n (%)
Female 10 (50%) 10 (50%)
Male 10 (50%) 10 (50%)
Age at diagnosis, years
Median (IQR) 62 (51–67) 61 (50–69)
Smoking
Never 16 15
Current 2 3
Ex-smoker 2 2
Alcohol
None 6 4
,10 units per week 7 14
10–20 units per week 3 0
21–30 units per week 2 1
.30 units per week 2 0
Aspirin
No 16 14
Yes 4 6
Colon cancer
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patients with colorectal cancer and non-cancer controls.
Antibodies to .5000 antigens were identified exclusively in
either group. Additionally, antibodies to .9000 antigens were
identified in both patients with and without cancer.
Analysis of the antibody repertoire
All positives identified on the array were ranked according to
statistical significance to discriminate between patients with
cancer and controls, using Fisher exact test. Antibodies to 43
antigens in the cancer group and 9 antigens in the non-cancer
control group, identified in the training set, correlated sig-
nificantly with the presence or absence of colorectal cancer. To
characterise the total patient cohort we then expanded the
sample size and re-analysed the p values for the entire patient
cohort. Of the antigens identified in the training set, 18 antigens
from the cancer group and 4 from the non-cancer group were
confirmed in this extended set (table 2).
We then set out to determine combinations of antigens that
could discriminate between patients with and without color-
ectal cancer. All 18 antigens (table 2) derived from the training
set and the extended set were examined separately. Starting
with the antigen most significantly associated with cancer
versus the non-cancer group (lowest p value), a predictive
ability was calculated based on specificity and sensitivity. By
adding next ranked antigens stepwise, the predictive ability of
the combined antigens was reassessed until the optimal
combination was found. The analysis resulted in a subset of
12 antigens discriminating between 43 patients with colorectal
cancer and 40 control patients without cancer with 80%
specificity and 83.7% sensitivity.
Identified cancer antigens
Analysis of the array data in the training set and the extended
set identified 18 antigens in the cancer group and 4 antigens
associated with absence of cancer (table 2). These antigens
range from membrane proteins (TSLC1 (tumour suppressor in
lung cancer 1)), cytoplasmic proteins (SNP29), nuclear proteins
(p53) to hypothetical proteins (FLJ10154). Apart from clone
G19547 expressing p53, all markers and antimarkers listed in
table 2 were expressed by one cDNA clone. An additional p53
clone (E16568) expressed a shorter, 178 amino acid p53
fragment immunoreactive with four colorectal cancer sera.
The length of identified antigens varied from large fragments to
full-length cDNA clones (online supplementary table S1).
Accumulation of p53 protein in tumour cells is known to
trigger p53 antibody production in patients with colorectal
cancer.22–24 In our study, antibodies to p53 were identified in
19% of patients with colorectal cancer and were absent in non-
cancer controls. The expression of p53 is a well recognised
marker of cancer; thus we characterised p53 protein expression
in our patient cohort to confirm the utility of our approach.
Tissue samples from excised cancers were examined. TMAs
were constructed from the same group of patients used in the
serum screening. Immunohistochemistry results showed that
p53 stained weakly in normal colorectal tissue, whereas 51%
(22/43) of colorectal cancer tissues stained strongly for p53
(fig 4A), correlating with advanced tumour stages (fig 4B). Anti-
p53 antibodies were found to be present in seven cancer patients
strongly expressing the protein in the tumour tissue (fig 4C).
One patient, who was positive for p53 antibody in serum, did
not stain for p53 in tissue. At the gene expression level, p53
mRNA was elevated in tumour tissue compared with adjacent
normal tissue in 13 of the 16 (81%) patients examined
(p = 0.002) (fig 4D).
We assessed the 18 identified cancer markers in relation to
Dukes stages in patients. Of the 8 patients with serum antibody
to p53, 1 patient was diagnosed Dukes A and 1 patient Dukes B,
while 2 patients were Dukes C and 4 were Dukes D. These data
suggest that the presence of serum p53 antibodies may correlate
with advanced stage in colorectal cancer. While p53 antibodies
may correlate with advanced Dukes stage, the other 17 antigens
do not show such a trend.
Molecular targets in colorectal cancer
p53 and other proto-oncogenes such as HER-2/neu are known
to trigger antibody responses in patients with cancer and are
associated with tumour pathogenesis.25 26 HMGB1 is postulated
to be an oncoprotein and has been implicated in the pathogen-
esis of colorectal cancer, but there is a paucity of literature on
the antibody profile in patients with colorectal cancer.27 28
Therefore, we investigated the expression of HMGB1 in tissue.
Figure 5A shows representative images of HMGB1 staining in
tumour tissue. We identified nuclear staining for HMGB1 in
93% (40/43) of tumour tissue samples and in 97% (37/38) of
normal colorectal tissue from the same patients (fig 5B). The
nuclear localisation of HMGB1 was in concordance with
previous studies.29 We did, however, detect cytoplasmic staining
in subpopulations of tumour cells. Sixty-seven percent (29/43)
of tumours showed cytoplasmic staining for HMGB1, whereas
Figure 2 Algorithm for the antibody signatures.
Colon cancer
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only 5% (2/38) of normal tissue samples from the same patients
showed cytoplasmic HMGB1 localisation (p,0.0001). We also
analysed the expression of HMGB1 in tissue of patients without
cancer. All 19 cases showed nuclear staining and 11% (2/19)
showed an additional cytoplasmic staining for HMGB1. These
findings suggest that cytoplasmic expression of HMGB1 occurs
preferentially in malignant cells and may have implications in
tumour pathogenesis. At the gene expression level, similar
results were found for HMGB1 as for p53, with 13 of 16 patients
(81%) showing elevated expression of HMGB1 mRNA in
tumour compared with matched normal tissue (p = 0.001).
In addition to p53 and HMGB1, we also examined mRNA
levels of TSLC1, a marker identified in the screen that has been
implicated in cancer.30 We also examined a number of these
markers whose role in cancer is unclear. Gene expression of
TSLC1, TRIM28, LASS5 (longevity assurance gene homologue
5), TCF3 (transcription factor 3; E2A immunoglobulin enhan-
cer-binding factors E12/E47) and zinc finger motif genes
ZNF346, ZNF638, ZNF700 and ZNF768 were examined in
matched tumour and normal tissue. The majority of patients
also showed elevated mRNA expression levels of TRIM28,
LASS5, TCF3 and ZNF346 in tumour tissue compared with
matched normal colonic tissue (fig 6). mRNA levels of TSLC1,
ZNF638, ZNF700 and ZNF768 were elevated in a small number
of patients, but not to a statistically significant level (online
supplementary fig S1).
DISCUSSION
The aim of this study was to determine if large-scale protein
arrays could identify antibodies that discriminate between
symptomatic patients who warranted colonoscopy with and
without cancer. We show that the antibody profile between
these two sets of patients is different. By examining tissue from
these cohorts we confirmed that there was a correlation
between p53 antibodies and expression in tissue in patients
with colorectal cancer. To validate the relevance of the
antibodies detected in the colorectal cancer group further we
investigated the tissue expression of identified antigens. The
aberrant tissue expression of the novel antigen HMGB1 and the
upregulation of mRNA levels of TRIM28 and several other
Figure 3 The frequency distribution of antibodies among patients with colorectal cancer and non-cancer controls is heterogeneous. The x-axis shows
the cumulative number of non-cancer controls. The percentage is shown below. The y-axis shows the cumulative number of patients with colorectal
cancer. The percentage is shown at the side. The numbers in the grid are the numbers of clones identified—for example, the red circled grid showing 4
indicates that four different clones were found to be immunoreactive with sera of 7 (18%) non-cancer controls (x-axis) and 17 (40%) patients with
colorectal cancer (y-axis).
Colon cancer
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genes confirm that our approach of screening high-density
protein arrays identifies biologically relevant antigens discrimi-
nating between two cohorts of patients. Thus our results show
that antibody detection discriminates between these cohorts of
patients.
Several technologies have been used to identify cancer-specific
antibodies. Peptide libraries derived from tumour tissue using
phage display have revolutionised the search for cancer
antigens.31 However, technological difficulties have hampered
the identification of complex antibody repertoires. In the
present study, protein arrays represent a powerful alternative
approach for identifying potential markers in a high-throughput
format, as .10 000 different proteins can be simultaneously
analysed. The majority of these proteins are in the correct
reading frame and are expressed as full-length forms or large
fragments of the original protein.14 15 Moreover, the identities of
the ‘‘positive’’ proteins are known or can be readily charac-
terised, allowing a biological interpretation of the results.19
While antibodies for the same antigen may not be detected if
their epitope is missing in a non-full length cDNA clone or where
splice variants are not present on the array, nevertheless this
approach of screening large protein arrays has identified
discriminatory profiles in patients with and without colon cancer.
Using the high-density (hEx1) protein arrays as a key
technology, we were able to identify thousands of proteins
immunoreactive with IgG antibodies in patients. The vast
numbers of antigen–antibody interactions identified reflects the
complexity of humoral immune responses and demonstrates
potential problems accompanying other technologies using
pooled sera with a reduced number of clones in follow-up
screenings, since antigens identified from pools of sera may lack
specificity to cancer and may originate from non-malignant
conditions shared by the patients.
The finding that several known antibodies identified in this
study were previously described in other cancers shows that
many of the pathways of tumourigenesis may be shared by
different cancers. Moreover, screening the arrays used in this
study with samples from patients with inflammatory bowel
disease to see if the antigens identified are similar to those with
colorectal cancer may well identify new pathways in the
pathogenesis of colon cancer.
Our results demonstrate previously described antigens to
colorectal cancer such as the tumour suppressor p53.
Correlation of p53 antibodies with p53 protein expression in
cancer tissue further validates this approach.23 26 Anti-p53
serum antibodies have been successfully used as predictors of
other cancers.32–34 However, despite their specificity, p53
antibodies are unsuitable for population screenings, as only
20–30% of patients with colorectal cancer have these
antibodies.26 The combination of several antigens with high
specificity may prove effective in clinical decision making such
as referral for colonoscopy, or potentially may assist in
treatment or diagnosis of recurrent disease.35 We performed a
stepwise procedure to assess the predictive ability of the
marker set and identified a highly specific and sensitive set of
12 markers. The predictive ability of the marker set was also
corrected using statistical methods. When a Bonferroni
correction at a level of a= 0.05 was applied to our set of 18
markers and 4 antimarkers, this resulted in a set of 7 markers
and 2 antimarkers with statistical significance for multiple
testing. The Bonferroni correction is, however, a conservative
method and, when applied to our marker set, it excluded
markers such as HMGB1 or TRIM28 which we show to be of
biological relevance. Using the less restrictive FDR, we found
14 of 18 markers and all 4 antimarkers with statistical
significance for multiple testing.
Table 2 Markers and antimarkers identified in serum screening
Protein name Swiss-prot ID RZPD clone ID
Colorectal cancer
(n = 43)
Non-cancer controls
(n = 40) p Value
Markers for colorectal cancer
Protein ITFG3 ITFG3 I23580 17 3 0.001b,w
Zinc finger protein 700 ZNF700 O10579 9 0 0.003b,w,z
Tumour suppressor in lung cancer 1 TSLC1 L03527 9 0 0.003b,w,z
Longevity assurance gene homologue 5 LASS5 M17513 8 0 0.006b,w,z
Cellular tumour antigen p53 P53 G19547 8 0 0.006b,w,z
Zinc finger protein 768 ZNF768 D15597 14 3 0.006b,w
Synaptosomal-associated protein 29 SNP29 M02600 12 2 0.007b,w,z
Zinc finger protein 638 ZNF638 I12603 13 3 0.012w,z
Methylosome subunit pICln ICLN G07590 7 0 0.012w,z
Zinc finger protein 346 ZNF346 P11513 11 2 0.014w,z
Erythrocyte band 7 integral membrane protein STOM N24509 14 4 0.016w
E2A immunoglobulin enhancer-binding factors E12/E47 TCF3 B13599 6 0 0.026w,z
KIAA0310 protein A0PJ75 N17517 6 0 0.026w,z
Transcription cofactor vestigial-like protein 4 VGLL4 O11570 10 2 0.027w
High mobility group protein B1 HMGB1 B12538 8 1 0.03z
Tripartite motif-containing protein 28 TRIM28 C11583 8 1 0.03
Heterogeneous nuclear ribonucleoprotein D-like HNRDL F16591 17 7 0.032
Unnamed protein product BAC85857 L03561 11 3 0.039z
Antimarkers for absence of cancer
Hypothetical protein FLJ10154 FLJ10154 M12552 3 13 0.005b,w
28S rRNA NR_003287 E17585 4 12 0.025b,w
Positive regulatory domain II-binding factor 1 ZEP1 C23550 1 7 0.026w
Protein FAM59A FA59A E09582 8 17 0.03w
The analysis of serum from 43 patients with colorectal cancer and 40 non-cancer controls identified these 18 antigens associated with colorectal cancer (p,0.05) and 4 antigens
associated with non-cancer controls (p,0.05). p values were calculated using two-sided Fisher exact test.
Corrected for multiple testing: bBonferroni; wfalse discovery rate (FDR); zstepwise analysis.
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Figure 4 Overexpression of tumour
suppressor p53 in colorectal cancer
tissue correlates with advanced Dukes
stages and p53 serum antibodies in
patients with colorectal cancer. (A)
Representative examples of tissue
microarray-based immunohistochemical
(IHC) staining using monoclonal antibody
to p53 (DO-7) (620). (a) Normal
colorectal mucosa with weak nuclear p53
staining. (b) Colorectal carcinoma with
strong nuclear p53 staining. (B) The
intensity of p53 staining in tumour tissue
increases with advanced Dukes stage as
identified by immunohistochemical
analysis of all 43 examined cases. (C)
Serum antibodies to p53 correlate with
expression of p53 protein in cancer
tissue. (D) p53 gene expression is
significantly elevated in colorectal
tumours compared with adjacent normal
tissue. (a) Ratios between p53 expression
at the mRNA level in tumour tissue
compared with adjacent normal tissue in
16 patients, mean (SE). (b) The graph
represents the gene expression at the
mRNA level in colorectal tumour and
matched normal colonic tissue; the line
represents the average expression in
either tumour or normal tissue. The p
value was calculated using Wilcoxon
rank-sum.
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The humoral immune response may be used for diagnosis but
may also elucidate mechanisms of the disease.11 The HMGB1
protein identified in this study may have a role in suppression of
antitumour immunity.36 HMGB1 is a non-histone chromatin-
associated protein with a variety of roles including transcrip-
tional regulation37 and DNA repair,38 and it functions as a
cytokine.39 It has been implicated in chemotherapy resis-
tance40 41 and in tumour metastasis.42 HMGB1 is postulated to
be an oncoprotein and its protein expression has been shown to
be altered in a variety of human cancers.43 We show that
HMGB1 mRNA is elevated in colorectal cancer tissue compared
with matched normal colon tissue, a finding also found by Yu et
al.44 At the protein level, HMGB1 has been shown to be
overexpressed in colorectal cancer.27 28 While HMGB1 has been
implicated in the pathogenesis of colorectal cancer, there is a
scarcity of literature on the antibody profile in patients with
colorectal cancer.27 28
Using immunohistochemistry, we showed nuclear localisa-
tion of HMGB1, which was in concordance with previous
studies.29 Moreover, we also found that HMGB1 was more
frequently present in cytoplasm of cancer cells than in cells from
normal colorectal tissue from the same patients. The predomi-
nant cytoplasmic expression of HMGB1 in malignant cells
suggests a potential mechanism in eliciting antibody production
to this antigen.
Examination of mRNA levels of markers identified in this
study indicates that some of these markers are elevated in
colorectal cancer tissue. Of those genes that were found to be
differentially expressed at the mRNA level, little is known about
their relationship to cancer. The transcriptional co-repressor
TRIM2845 was previously linked with coordination of cellular
DNA damage responses,46–48 differentiation of embryonal
carcinoma cells49 and a transcriptional regulator of the
interleukin-6 (IL-6)/signal transducer and activator of transcrip-
tion 3 (STAT3) signalling pathway.50 The transcription factor
TCF3 is a transcriptional repressor of E-cadherin, implicated in
epithelial to mesenchymal transition, and may be linked to
tumour aggressiveness.51 Additionally it is involved in the Wnt
signalling cascade, which is linked to colorectal cancer progres-
sion.52 LASS5 is a C16 ceramide synthase53; ceramides play a role
in apoptosis and may act in modulating response to chemother-
apeutic agents.54 Members of the LASS family have been shown
Figure 5 High mobility group B1
(HMGB1) is expressed aberrantly in
colorectal cancer tissue. (A)
Representative examples of tissue
microarray-based immunohistochemical
(IHC) staining using monoclonal antibody
to HMGB1 (M02/1D5) (620). (a) Normal
colorectal mucosa showing nuclear
staining for HMGB1 with no cytoplasmic
staining. (b) Colorectal carcinoma
showing nuclear staining for HMGB1 with
no cytoplasmic staining. (c) Colorectal
carcinoma showing nuclear and strong
cytoplasmic staining for HMGB1. (B)
Cytoplasmic staining for HMGB1 was
identified in 67% of colorectal
carcinomas. The p value was calculated
using two-sided Fisher exact test. (C)
HMGB1 mRNA expression levels are
significantly elevated in colorectal
tumours compared with adjacent normal
tissue. (a) Ratios between HMGB1
expression at the mRNA level in tumour
tissue compared with adjacent normal
tissue in 16 patients, mean (SE). (b) The
graph represents the HMGB1 gene
expression at the mRNA level in
colorectal tumour and matched normal
colonic tissue; the line represents the
average expression in either tumour or
normal tissue. The p value was calculated
using Wilcoxon rank-sum.
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to be involved in cell growth regulation, cancer differentiation
and response to chemotherapy.55 ZNF346 may play a role in cell
growth and survival, and when ectopically expressed induces
apoptosis.56 The differential increase in the expression of these
genes in colorectal cancer tissue suggests that these proteins
may play a role in the pathogenesis of colorectal cancer.
Our screening studies demonstrate the complexity of anti-
body responses in patients with and without cancer. The
process by which these and other self proteins become
immunogenic is not yet understood.57 Progression of cancer
correlates with enhanced deregulation of key signalling path-
ways58 and therefore different stages of cancer may trigger
different antibody profiles. In this study we showed that p53
antibodies correlated with advanced Dukes stage, while other
antibodies were found in patients with all stages of cancer.
Since early detection of cancer is a key factor in patients’
outcome, a combination of markers encompassing all stages of
cancer may aid in earlier detection of the disease. Another
interesting feature of our study was the detection of four
antibodies in symptomatic patients associated with absence of
cancer. Such antimakers may help decide if colonoscopy
procedures are required or may suggest mechanisms that are
downregulated in the pathogenesis of cancer.
In summary, we show for the first time that screening serum
from symptomatic patients with large protein arrays identifies
both known and new antibodies that may have a role in the
diagnosis and treatment of patients with colorectal cancer.
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